[ad_1]
Next year, Richard Bergström expects vaccinations against the coronavirus to begin. But it may take some time before there is protection for all sectors of the population.
– We will have a good vaccine for the entire population, but not tomorrow, not in the first trimester, nor in the second trimester, but at the end of next year or the beginning of the following year, says Richard Bergström.
One of the companies with which Sweden has signed an agreement is the pharmaceutical company Astra Zeneca.
– As we graduate with different types of vaccines, we will have a good flow next year, but it will be limited at first, says Richard Bergström in Aktuellt.
At least 500 million doses
There is currently no coronavirus vaccine that has been approved.
Richard Bergström, for his part, is not concerned about overpromising when it comes to delivering vaccines in the next few years.
– We have different technologies in which we invest, different companies and different manufacturers. So I feel safe saying that next year the EU will have access to at least 500 million doses, says Richard Bergström in Aktuellt.
“It looks promising”
The effects have been questioned and no vaccine provides 100% protection. Gunilla Karlsson Hedestam, a professor of vaccine immunology at Karolinska Institutet, has previously criticized the decision to sign deals on millions of doses of vaccine where no results have yet been seen.
However, Richard Bergström is optimistic.
– Looks promising so far.
– But we have to see if they have a protective effect, which we see in the results of phase 3, he says.
Understand uncertainty
At the same time, there is some concern among the population regarding the new vaccines that are now being developed. Mostly due to the side effects of the swine flu vaccine a few years ago.
– We have no reason to believe that these vaccines carry a higher risk of side effects than others.
But are there any risks?
– The risk is always there. There are no medications or vaccines that are completely safe. But we ran large trials with 30,000-50,000 people to check for rare side effects, says Richard Bergström.
Here you can see the whole part of Aktuellt that dealt with vaccines.
